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ined the impact of changes in private drug plan formulary design
on the health of private plan beneﬁciaries. METHODS: A search
of the medical literature was conducted using the PubMed search
engine. Search terms included combinations of reimbursement,
formulary, plan, payer, restriction, cost, and adherence. The
‘related articles’ feature in PubMed was also used to identify
relevant papers. RESULTS: While no published studies of Cana-
dian employer-sponsored drug plans were identiﬁed, there were
15 North American studies that focused on the effects of changes
in drug plan design. This body of research demonstrated three
key points. Cost-sharing initiatives resulted in a reduction, or
complete cessation, of medication consumption, including
drugs deemed “essential”, and that decreased adherence to drug
therapy can actually lead to the increased use of other more
expensive health care resources. On the other hand, higher levels
of medication adherence, which increased drug costs, were asso-
ciated with lower overall health care costs. Employee satisfaction
with their employer drug plan decreased when cost-containment
measures were implemented and this is a problem for employers
since drug plan changes typically involved increasing fees or
imposing more restrictions to access. CONCLUSION: A short-
term focus on controlling drug costs is likely to have negative
consequences on the health, productivity and satisfaction of plan
members. If changes to drug plans are not properly assessed,
there can be undesirable and expensive consequences for plan
members and employers. Employers need a longer term frame-
work to guide and support health plan decision-making that
avoids sudden or drastic changes to health beneﬁts. Careful
consideration of drug plan design and cost-sharing can improve
medication adherence, health outcomes, employee satisfaction,
and costs.
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OBJECTIVES: While pharmaceuticals can signiﬁcantly improve
the health of patients and help to mitigate health-related inequi-
ties within a population, their rising prominence within health
systems is not without challenges. This paper explores health
related aspects of pharmaceutical policy in Australia, Canada,
Germany, The Netherlands, New Zealand, the UK and the
United States. METHODS: Drawing on published goals for
national policies, we developed a framework for gauging
pharmacare system performance. We review policy structures
and investigate system performance using preliminary indicators
drawn from the 2007 Commonwealth Fund Survey. Survey
responses to questions related to accessibility, affordability, and
appropriateness are compared across countries and stratiﬁed by
age, income and morbidity. RESULTS: Shares of populations
reporting prescription drug use were lowest in Germany and
highest in the US. Pharmaceutical use displayed expected age
gradients in all countries and expected income gradients in all but
Germany and the US. Cost-related non-adherence was most fre-
quent in the US and Australia, and relatively unlikely among
elderly populations. Relatively few patients reported prescribing
errors, with no signiﬁcant differences across countries. Out-of-
pocket drug costs were highest in the US and Canada. From 1995
to 2005, pharmaceutical expenditures outpaced health care and
GDP in all countries except New Zealand. Expenditure grew
most quickly in the US. CONCLUSION: Though no country
appears uniformly strong in all areas of pharmacare policy,
several appear to have done well to manage difﬁcult tensions in
the pharmaceutical sector.
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OBJECTIVE: Snyder and King (2007) developed a theoretical
model of ﬁrm behavior in which research and marketing activi-
ties are complements rather than substitutes. Public policy debate
frequently makes the implicit assumption that the two activities
are substitutes. In this paper the author uses ﬁnancial reports of
Fortune 200 pharmaceutical ﬁrms to examine the evidence for
Snyder and King’s theoretical model. METHODS: We extract
research and marketing expenditure totals from the quarterly
ﬁlings of the eight largest U.S. based pharmaceutical companies.
We also create a comparator list of non-pharmaceutical compa-
nies matched for size and using pre-speciﬁed exclusion criteria.
Univariate analysis is used to test whether pharmaceutical
companies are systematically different from the comparator com-
panies. Simple regression analysis is used to test whether com-
panies with higher research/revenue ratios have higher or lower
marketing/revenue ratios. RESULTS: Pharmaceutical ﬁrms spend
a greater share of revenue on both marketing and R&D than the
comparator ﬁrms. The share spent on marketing is similar to a
subgroup of the comparator ﬁrms. The share spent on research
is uniquely high. Pharmaceutical ﬁrms are also unique in their
combination of high marketing and high research spending.
Regression analysis shows no signiﬁcant relationship (positive or
negative) between research and marketing expenditure. CON-
CLUSION: Empirical analysis provides limited support to the
theory developed in Snyder and King (2007). The absence of
signiﬁcant regression results may be due to the time lag between
development and approval for sale.
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OBJECTIVE: The RIZIV/INAMI, the Belgian third-party payer,
aims to set reimbursement tariffs at a level that reﬂects costs of
orthotic braces. In the absence of publicly disclosed information
on the cost structure of braces, estimating production and distri-
bution costs of braces is valuable to reimbursement agencies with
a view to setting tariffs. The aim of this study is to calculate the
cost of production and distribution of a prefabricated hard neck
brace and a prefabricated hard knee brace, and to explore
whether Belgian tariffs and actual retail prices correspond with
estimated costs of these two braces. METHODS: The cost model
took into account manufacturing costs, general overhead,
research and development, warehousing, proﬁt and distribution
margins. Data were gathered from manufacturers, a visit to a
production site, desk research, a decomposition of ﬁnished prod-
ucts and interviews with stakeholders. The price year was 2007.
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RESULTS: The cost model generated an estimated retail price of
€55 or €113 for the neck brace depending on assumptions. The
estimated retail price for the neck brace was lower than the
reimbursement tariff of €194 and the actual retail price of €241.
With respect to the knee brace, the estimated retail price of €331
or €523 was inferior to the tariff of €580 and the actual retail
price of €948. CONCLUSION: Actual retail prices and reim-
bursement tariffs for two selected neck and knee braces substan-
tially exceeded retail prices based on estimated production and
distribution costs. Therefore, there seems to be scope for reduc-
ing reimbursement tariffs and containing public expenditure on
orthotic braces.
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OBJECTIVE: The Israeli National Health Insurance Law stipu-
lates aNational List ofHealth Services (NLHS)which all residents
are entitled from their HMOs. This list has been updated annually
for almost a decade using a structured review and decision-making
process. Although the Israeli explicit priority-setting experience is
unique and may be considered groundbreaking, its fairness and
legitimacy have not been assessed. To assess the priority-setting
process for compliance with the four conditions of accountability
for reasonableness outlined by Daniels and Sabin (relevance,
publicity, appeals, and enforcement), andwith the four steps of the
trans-disciplinary model for priority setting in health care (rea-
sonableness, transparency, responsiveness, and accountability).
METHODS: We used such data as public documents, audit
reports, literature review, the mass media, observations from the
meetings of the Public Adivosry Committee responsible for rec-
ommending new technologies for th NLHS, and interviews with
the committeemembers.RESULTS:The Israeili process for updat-
ing the NLHS does not fulﬁll the appeals and enforcement
conditions, and only partially follows the publicity and relevance
conditions, outlinesd in the accountabilty for reasonableness and
transparency framework. Only the reasonableness and transpar-
ency steps of the trans-disciplinary model are partially fulﬁlled,
but the priority setting process lacks responsiveness and account-
ability. CONCLUSION: The fairness and legitimacy of the
priority-setting mechanism have not been established. The main
obstacles for achieving these goals may relate to the large number
of technologies assessed each year within a short time frame (500
technologies assessed in 2007), the lack of personnel engaged in
health technology assessment and the desire for early adoption of
new technologies. Changes in the priority-setting process should
be made in order to increase its acceptability among the different
stakeholders.
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OBJECTIVE: Stakeholder involvement in health technology
assessment (HTA) is of growing importance, as their participa-
tion in and support of economic evaluation is generally con-
sidered to improve the assessment process and subsequent
implementation. Consequently, in early 2007, the Health Select
Committee of the UK House of Commons initiated a public
inquiry into the National Institute of Health and Clinical Excel-
lence (NICE), calling for comments from a variety of stake-
holders. This study aimed to examine stakeholder perspectives
on several topics, including public conﬁdence in NICE; appro-
priateness of economic evaluation methods; and, effectiveness of
guidance implementation. METHODS: All stakeholder submis-
sions (n = 92) were systematically reviewed and key themes were
identiﬁed across three principal categories: 1) organisation and
process; 2) methods; and 3) decision-making and implementa-
tion. RESULTS: Stakeholders identiﬁed a number of overarching
issues regarding NICE and economic evaluation, more broadly.
Firstly, despite its “arms-length” organisational structure, NICE
is perceived to lack independence. Secondly, stakeholders con-
tented that its methods assume an overly narrow perspective,
especially regarding the use of RCTs, QALYs, and measures of
costs and beneﬁts. Thirdly, commentators asserted that manufac-
turers, clinical experts, and patients should play a greater role in
HTA processes. Fourthly, the time taken to issue guidance was
considered an important limitation, especially given evidence
that local decision-makers delay the introduction of new treat-
ments pending NICE’s decision(s). Other key concerns included
inconsistent local implementation of guidance and the overall
transparency of NICE operations. CONCLUSION: Most stake-
holders support the overall role of NICE in the NHS, and
acknowledge that the Institute generally undertakes rigorous
assessments. Nevertheless, many criticisms were put forth by
stakeholders. NICE should continue to capitalise on its strengths,
while pioneering solutions to address existing limitations and
challenges. However, it is unlikely that any national HTA system
will satisfy the needs and expectations of all key parties.
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OBJECTIVE: To evaluate a methodology of managing high cost
patients, called Case Management Program (CMP), within a
private health plan in southern Brazil and show that such
program is cost-effective and the return on investment (ROI) is
positive. METHODS: Using NAGIS(c) model and software for
disease management program, the CMP was implemented in
211 patients (0.9% of the health plan beneﬁciaries). I compared
health plan utilization and costs including CMP costs of one
period of time before the program starts with the same period of
time that the program was in place. RESULTS: After 9 months of
CMP, there were 162 patients. I considered outcomes for these
162 patients. For one Real invested, R$4,78 was saved (One
2008 American Dollar is 1,78 Brazilian Real). The average cost
per enrollee per month reduced 45.9% (R$463,85 to R$250,89)
and 39.4% (R$463,85 to R$280,90) if the program’s costs
(direct and indirect costs) are included as ﬁxed costs. The number
of visits reduced by 11.3% (794 to 704), as well as the labs
exams which reduce 35.7% (420 to 270). Nevertheless, the labs
exams per visit index reduce by 27.5%, where almost 53% of the
visits had at least one exam before starting the program against
38.3% after the same period of time that the program starts. The
number of hospitalizations reduced 34.6%, from 483 to 316.
Thus, the bed-days saved were 554 days at inﬁrmaries and 62
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